Kiniksa Pharmaceuticals International plc

For the period ended Dec 31, 2024. Filed Feb 25, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Feb 25, 2025

KNSA$95.02-3.8%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 8. Consolidated Statements of Cash Flows

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)


· · Years Ended
· · December 31,
· 2024 · · 2023 · · 2022
Cash flows from operating activities: · · · · · · ·
Net income (loss)	$(43,193)	$14,084	$183,363
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation and amortization expense	1,695	2,341	2,402
Share-based compensation expense	30,693	27,149	25,120
Non-cash lease expense	3,136	3,054	3,041
Amortization (accretion) of discounts on short-term investments	441	(1,068)	(82)
Gain on disposal of property and equipment	(25)	—	—
Loss on disposal of property and equipment	1	179	33
Deferred income taxes	8,132	(33,788)	(185,495)
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(2,710)	(7,067)	(3,858)
Accounts receivable, net	(20,458)	(8,606)	(8,675)
Inventory	4,758	(9,523)	(17,924)
Contract asset	—	7,656	(7,656)
Other long-term assets	(9,735)	4,584	2,654
Accounts payable	(6,306)	347	6,031
Accrued expenses, accrued collaboration expenses and other current liabilities	43,729	16,940	(3,709)
Operating lease liabilities	(3,984)	(3,261)	(3,007)
Deferred revenue	19,550	261	12,000
Other long-term liabilities	(35)	19	1,569
Net cash provided by operating activities	25,689	13,301	5,807
Cash flows from investing activities:
Proceeds from sale of property and equipment	25	—	91
Purchases of property and equipment	(277)	(130)	(105)
Purchases of short-term investments	(202,014)	(204,933)	(135,864)
Proceeds from the maturities of short-term investments	239,938	175,506	127,800
Net cash provided by (used in) investing activities	37,672	(29,557)	(8,078)
Cash flows from financing activities:
Proceeds from issuance of Class A ordinary shares under incentive award plans and employee share purchase plan	17,250	3,701	3,417
Payments in connection with ordinary stock tendered for employee tax obligations	(4,984)	(2,206)	(901)
Net cash provided by financing activities	12,266	1,495	2,516
Net increase (decrease) in cash and cash equivalents	75,627	(14,761)	245
Cash and cash equivalents at beginning of period	107,954	122,715	122,470
Cash and cash equivalents at end of period	$183,581	$107,954	$122,715

Supplemental information:
Cash paid for income taxes, net	$2,003	$5,605	$10,689

Supplemental disclosure of non-cash investing and financing activities:
Change in right-of-use asset as a result of new, modified, and terminated leases	$1,581	$9,600	$2,876
Additions to property and equipment included in accrued expenses and other liabilities	$153	$54	$—

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.